ERBB2 and breast cancer: In a previous study by Groot et al. [27], 13 HER2-negative BC patients at Stage II/III were recruited, of whom 7 were randomized to IF (fasting 24 h before and after neoadjuvant TAC regimen: docetaxel/doxorubicin/cyclophosphamide).